Systemic treatment of brain metastases in HER2-positive breast cancer: Current status and future directions

Future Oncology

Volumn 8, Issue 2, 2012, Pages 135-144

  Azim, Hamdy A ^a   Azim, Hatem A ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

blood brain barrier; brain metastases; HER2 positive breast cancer; lapatinib; trastuzumab

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; SILDENAFIL; TAXANE DERIVATIVE; TEMOZOLOMIDE; TOPOTECAN; TRASTUZUMAB; VARDENAFIL; VINCA ALKALOID;

ADJUVANT CHEMOTHERAPY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG TRANSPORT; ERECTILE DYSFUNCTION; HAZARD RATIO; HUMAN; LUNG EMBOLISM; MORBIDITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK; THROMBOCYTOPENIA;

EID: 84857291505     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.149     Document Type: Article

References (77)

1. Kamar FG, Posner JB. Brain metastases. Semin. Neurol. 30(3), 217-235 (2010).
2. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 22(14), 2865-2872 (2004). (Pubitemid 41079905)
3. Miller KD, Weathers T, Haney LG et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann. Oncol. 14(7), 1072-1077 (2003). (Pubitemid 36950171)
4. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am. J. Pathol. 167(4), 913-920 (2005). (Pubitemid 41416243)
5. Lee SS, Ahn JH, Kim MK et al. Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res. Treat. 111(3), 523-530 (2008).
6. Musolino A, Ciccolallo L, Panebianco M et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 117(9), 1837-1846 (2011).
7. Pestalozzi BC, Zahrieh D, Price KN et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the international breast cancer study group (IBCSG). Ann. Oncol. 17(6), 935-944 (2006). (Pubitemid 43778983)
8. Kennecke H, Yerushalmi R, Woods R et al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 28(20), 3271-3277 (2010).
9. Azim HA, Malek RA, Abdelmonem D, Amin S, Abdelsalam M. Risk factors of brain metastasis in a series of Egyptian breast cancer patients: a single institution experience. J. Clin. Oncol. 29(Suppl. 27), Abstract 50 (2011).
10. Palmieri D, Bronder JL, Herring JM et al. HER-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 67(9), 4190-4198 (2007). (Pubitemid 46815065)
11. Hinton CV, Avraham S, Avraham HK. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin. Exp. Metastasis 27(2), 97-105 (2010).
12. Andre F, Cabioglu N, Assi H et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann. Oncol. 17(6), 945-951 (2006). (Pubitemid 43778984)
13. Andre F, Xia W, Conforti R et al. CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist 14(12), 1182-1188 (2009).
14. Azim H, Azim HA Jr. Targeting HER-2/neu in breast cancer: as easy as this! Oncology 74(3-4), 150-157 (2008).
15. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J. Clin. Oncol. 27(31), 5278-5286 (2009).
16. Brufsky AM, Mayer M, Rugo HS et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17(14), 4834-4843 (2011).
17. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15(2), 219-225 (2006).
18. Yau T, Swanton C, Chua S et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol. 45(2), 196-201 (2006).
19. Lampson LA. Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier. mAbs 3(2), 153-160 (2011).
20. Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PloS ONE 6(6), E21030 (2011).
21. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555), 29-36 (2007). (Pubitemid 46039831)
22. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005). (Pubitemid 41464706)
23. Dawood S, Gonzalez-Angulo AM, Albarracin C et al. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer 116(13), 3084-3092 (2010).
24. Le Scodan R, Jouanneau L, Massard C et al. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer 11(1), 395 (2011).
25. Xu Z, Marko NF, Chao ST et al. Relationship between HER2 status and prognosis in women with brain metastases from breast cancer. Int. J. Radiat. Oncol. Biol. Phys. doi:10.1016/j.ijrobp.2011.06.1968 (2011) (Epub ahead of print).
26. Lower EE, Drosick DR, Blau R, Brennan L, Danneman W, Hawley DK. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin. Breast Cancer 4(2), 114-119 (2003). (Pubitemid 36939417)
27. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101(4), 810-816 (2004). (Pubitemid 39030939)
28. Bartsch R, Rottenfusser A, Wenzel C et al. Trastuzumab prolongs overall survival in patients with brain metastases from HER2 positive breast cancer. J. Neurooncol. 85(3), 311-317 (2007). (Pubitemid 350142522)
29. Dawood S, Broglio K, Esteva FJ et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann. Oncol. 19(7), 1242-1248 (2008). (Pubitemid 351911952)
30. Church DN, Modgil R, Guglani S et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am. J. Clin. Oncol. 31(3), 250-254 (2008).
31. Park IH, Ro J, Lee KS, Nam BH, Kwon Y, Shin KH. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann. Oncol. 20(1), 56-62 (2009).
32. Witzel I, Kantelhardt EJ, Milde-Langosch K et al. Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer. Onkologie 34(6), 304-308 (2011).
33. Pinder MC, Chang H, Broglio KR et al. Trastuzumab treatment and the risk of central nervous system (CNS) metastases. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2007.
34. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006). (Pubitemid 46021510)
35. Cameron D, Casey M, Press M et al. A Phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 112(3), 533-543 (2008).
36. Gril B, Palmieri D, Bronder JL et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J. Natl Cancer Inst. 100(15), 1092-1103 (2008).
37. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 26(12), 1993-1999 (2008).
38. Lin NU, Dieras V, Paul D et al. Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 15(4), 1452-1459 (2009).
39. Lin NU, Eierman W, Greil R et al. Randomized Phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J. Neurooncol. 105(3), 613-620 (2011).
40. Cardoso F, Bedard PL, Winer EP et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J. Natl Cancer Inst. 101(17), 1174-1181 (2009).
41. Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J. Neurooncol. 85(2), 223-227 (2007). (Pubitemid 47629405)
42. Boccardo F, Kaufman B, Baselga J et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU). Presented at: 2008 ASCO Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
43. Sutherland S, Ashley S, Miles D et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases -the UK experience. Br. J. Cancer 102(6), 995-1002 (2010).
44. Metro G, Foglietta J, Russillo M et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann. Oncol. 22(3), 625-630 (2011).
45. Bachelot TD, Romieu G, Campone M et al. LANDSCAPE: an FNCLCC Phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR). Presented at: 2011 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2011.
46. Lin NU, Ramakrishna N, Younger WJ et al. Phase I study of lapatinib (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer. Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
47. Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 13(6), 1663-1674 (2007). (Pubitemid 46952931)
48. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res. 24(9), 1745-1758 (2007). (Pubitemid 47206624)
49. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J. Clin. Oncol. 25(16), 2306-2312 (2007).
50. Lockman PR, Mittapalli RK, Taskar KS et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin. Cancer Res. 16(23), 5664-5678 (2010).
51. Yonemori K, Tsuta K, Ono M et al. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 116(2), 302-308 (2010).
52. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75(4), 725-748 (1995).
53. Bentley JK, Beavo JA. Regulation and function of cyclic nucleotides. Curr. Opin Cell Biol. 4(2), 233-240 (1992).
54. Corbin JD, Beasley A, Blount MA, Francis SH. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochem. Int. 45(6), 859-863 (2004). (Pubitemid 39108058)
55. Black KL, Yin D, Ong JM et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res. 1230, 290-302 (2008).
56. Hu J, Ljubimova JY, Inoue S et al. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PloS ONE 5(4), E10108 (2010).
57. Ding PR, Tiwari AK, Ohnuma S et al. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PloS ONE 6(4), E19329 (2011).
58. Agarwal S, Hartz AM, Elmquist WF, Bauer B. Breast cancer resistance protein and p-glycoprotein in brain cancer: two gatekeepers team up. Curr. Pharm. Des. 17(26), 2793-2802 (2011).
59. Gong J, Jaiswal R, Mathys JM, Combes V, Grau GE, Bebawy M. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat. Rev. doi:10.1016/j. ctrv.2011.06.005 (2011) (Epub ahead of print).
60. Ruff P, Vorobiof DA, Jordaan JP et al. A randomized, placebo-controlled, double-blind Phase 2 study of docetaxel compared with docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother. Pharmacol. 64(4), 763-768 (2009).
61. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5(3), 219-234 (2006). (Pubitemid 43336035)
62. Dai CL, Tiwari AK, Wu CP et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 68(19), 7905-7914 (2008).
63. De Azambuja E, Lemort M, Rossari JR et al. Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172). Presented at: 2011 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2011.
64. Stupp R, Mason WP, Van Den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005). (Pubitemid 40349501)
65. Mehta MP, Paleologos NA, Mikkelsen T et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 96(1), 71-83 (2010).
66. Addeo R, De Rosa C, Faiola V et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 113(9), 2524-2531 (2008).
67. Siena S, Crino L, Danova M et al. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter Phase II study. Ann. Oncol. 21(3), 655-661 (2010).
68. Vannini I, Zoli W, Fabbri F et al. Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines. Anticancer Drugs 20(10), 918-925 (2009).
69. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg. 83(6), 1029-1037 (1995). (Pubitemid 26048143)
70. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev. 88(3), 887-918 (2008).
71. Bu G, Maksymovitch EA, Geuze H, Schwartz AL. Subcellular localization and endocytic function of low density lipoprotein receptor-related protein in human glioblastoma cells. J. Biol. Chem. 269(47), 29874-29882 (1994). (Pubitemid 24365153)
72. Demeule M, Currie JC, Bertrand Y et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem. 106(4), 1534-1544 (2008).
73. Thomas FC, Taskar K, Rudraraju V et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm. Res. 26(11), 2486-2494 (2009).
74. Sarantopoulos J, Gabrail NY, Moulder SL et al. ANG1005: results of a Phase I study in patients with advanced solid tumors and brain metastases. Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2011.
75. Chargari C, Idrissi HR, Pierga JY et al. Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 81(3), 631-636 (2011).
76. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28(7), 1124-1130 (2010).
77. Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy. http://clinicaltrials.gov/ct2/show/ NCT00903656